Using the drop-down menu below, read about highlighted scientific news for patients from ASCO's Annual Meetings, Symposia, and medical journals for the past three years. You can select a specific year, meeting or publication, and/or a specific topic, such as a type of cancer. Selecting "All" will take you to a complete list of articles that appear under all categories.
The 2014 event was held May 30-June 3. The next ASCO Annual Meeting will be held May 29-June 2, 2015, in Chicago. To read the Annual Meeting summaries compiled into a yearly newsletter, you can also review Research Round Up: News for Patients from the ASCO Annual Meeting. Don’t forget to check out audio podcasts and videos about this news, as well. And a list of upcoming Symposia can be found here. And, in addition to the highlighted studies below, thousands of scientific abstracts are released each year at different ASCO meetings. To search the entire collection of meeting abstracts, visit ASCO's website.
Early results from an ongoing phase II clinical trial have shown that a new chemotherapy combination, CAPTEM, may be an effective second-line treatment option for patients with a neuroendocrine tumor that has spread to other parts of the body, even for tumors that haven’t responded to other standard (commonly used) treatments. A second-line treatment is given if the first treatment does not work, starts but then stops working, or causes serious side effects. CAPTEM combines two drugs, capecitabine (Xeloda) and temozolomide (Temodar), which are given in a specific order—capecitabine first, temozolomide second—based on research that showed this might be more effective than giving both drugs at the same time.
New results from a large clinical trial show that a drug taken by mouth is just as effective as one given by infusion for people with stage II or stage III rectal cancer. These patients received radiation therapy and chemotherapy with either capecitabine (Xeloda) or 5-fluorouracil (5-FU, Adrucil) before surgery. The researchers also found that adding another drug, oxaliplatin (Eloxatin), did not provide any additional benefits and caused more side effects.
A large study shows that testing for specific genetic changes in tumor cells can tell doctors whether people with metastatic colorectal cancer (colorectal cancer that has spread to other parts of the body) are likely to benefit from combining second-line chemotherapy with a targeted therapy called panitumumab (Vectibix). A second-line treatment is given if the first treatment does not work, starts but then stops working, or causes serious side effects.
Combining the chemotherapy drug paclitaxel (Taxol) with a monoclonal antibody known as ramucirumab helps people with stomach or gastroesophageal junction (GEJ, lower part of the esophagus that connects to the stomach) cancer that has spread to other parts of the body live longer than paclitaxel treatment alone, according to a new study. These treatments were given as second-line therapy (treatment given if the first does not work, starts but then stops working, or causes serious side effects). The researchers also noted that people who received the drug combination reported a better quality of life.
Researchers have found that treatment with two different vaccines, GVAX Pancreas followed by CRS-207, helps people with metastatic pancreatic ductal adenocarcinoma (PDAC) live longer. PDAC is the most common type of pancreatic cancer. This study shows that immunotherapy (treatment designed to boost the body's natural defenses to fight the cancer) can help treat pancreatic cancer and appears to cause less serious side effects than chemotherapy.